Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2013 1
2017 1
2018 1
2019 2
2020 2
2021 6
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D. Fattori S, et al. Among authors: pakradouni j. Cancer Res. 2023 Sep 15;83(18):3026-3044. doi: 10.1158/0008-5472.CAN-23-0613. Cancer Res. 2023. PMID: 37379438 Free PMC article.
The CCN family: a new class of inflammation modulators?
Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C. Kular L, et al. Among authors: pakradouni j. Biochimie. 2011 Mar;93(3):377-88. doi: 10.1016/j.biochi.2010.11.010. Epub 2010 Dec 2. Biochimie. 2011. PMID: 21130134 Review.
Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients.
Lopresti A, Acquaviva C, Boudin L, Finetti P, Garnier S, Aulas A, Liberatoscioli ML, Cabaud O, Guille A, de Nonneville A, Da Costa Q, Denicolai E, Pakradouni J, Goncalves A, Birnbaum D, Bertucci F, Mamessier E. Lopresti A, et al. Among authors: pakradouni j. Cancers (Basel). 2022 Feb 13;14(4):932. doi: 10.3390/cancers14040932. Cancers (Basel). 2022. PMID: 35205679 Free PMC article.
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, Birnbaum D, Chaffanet M. Bertucci F, et al. Among authors: pakradouni j. Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9. Genome Med. 2021. PMID: 34006291 Free PMC article. Clinical Trial.
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
Billon E, Gravis G, Guille A, Carbuccia N, Adelaide J, Garnier S, Finetti P, Denicolaï E, Sfumato P, Brunelle S, Thomassin-Piana J, Pignot G, Walz J, Chabannon C, Pakradouni J, Sabatier R, Vicier C, Popovici C, Mamessier E, Gonçalves A, Birnbaum D, Chaffanet M, Bertucci F. Billon E, et al. Among authors: pakradouni j. Cancers (Basel). 2022 May 3;14(9):2275. doi: 10.3390/cancers14092275. Cancers (Basel). 2022. PMID: 35565404 Free PMC article.
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Sabatier R, Vicier C, Garnier S, Guille A, Carbuccia N, Isambert N, Dalenc F, Robert M, Levy C, Pakradouni J, Adelaïde J, Chaffanet M, Sfumato P, Mamessier E, Bertucci F, Goncalves A. Sabatier R, et al. Among authors: pakradouni j. Mol Oncol. 2022 May;16(10):2057-2070. doi: 10.1002/1878-0261.13188. Epub 2022 Mar 30. Mol Oncol. 2022. PMID: 35122700 Free PMC article. Clinical Trial.
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, Wlosik J, Orlanducci F, Gorvel L, Fattori S, Hospital MA, Pakradouni J, Gregori E, Paul M, Rochigneux P, Pagliardini T, Morey M, Fauriat C, Dulphy N, Toubert A, Luche H, Malissen M, Blaise D, Nunès JA, Vey N, Olive D. Chretien AS, et al. Among authors: pakradouni j. Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2020459118. doi: 10.1073/pnas.2020459118. Proc Natl Acad Sci U S A. 2021. PMID: 34050021 Free PMC article.
High Response to Cetuximab in a Patient With EGFR-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.
Sabatier R, Lopez M, Guille A, Billon E, Carbuccia N, Garnier S, Adelaide J, Extra JM, Cappiello MA, Charafe-Jauffret E, Pakradouni J, Viens P, Gonçalves A, Chaffanet M, Birnbaum D, Bertucci F. Sabatier R, et al. Among authors: pakradouni j. JCO Precis Oncol. 2019 Dec;3:1-8. doi: 10.1200/PO.18.00310. JCO Precis Oncol. 2019. PMID: 35100682 No abstract available.
20 results